ArticlePublished 4 Jan 2024
Study of the Effects of Risankizumab in Moderate to Severe Crohn?s Disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
To study the effect of risankizumab in moderate to severe Crohn's disease. In the trial, 80 patients with moderate-to-severe Crohn’s disease who were hospitalized to our hospital between January 2021 and January 2022 were randomly assigned to the risankizumab group (n=40, with risankizumab added to conventional treatment) or the placebo group (n=40, with placebo added to conventional treatment) to compare the clinical efficacy, inflammatory indexes, incidence of adverse effects and quality of life of the two groups scores. The clinical remission rate and endoscopic remission rate were both higher in the risankizumab group than in the placebo group (p<0.05). After therapy, the risankizumab group had lower levels of C-reactive protein, platelet count, erythrocyte sedimentation rate, all quality of life scores, and the frequency of adverse reactions than the placebo group, while the mean platelet volume was higher than the placebo group (p<0.05). Risankizumab is effective in treating moderate to severe Crohn’s disease, relieving the inflammatory state of the body, reducing the occurrence of adverse effects and improving quality of life.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalIndian Journal of Pharmaceutical Sciences
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Yuan Fang”
- BylineArticles whose byline prints “Jipeng Li”
- BylineArticles whose byline prints “J. Wu”
- BylineArticles whose byline prints “Luxi Zhang”